MiR-192 has tumor-suppressive functions in RCC by inhibiting cell migration, invasion, and epithelial-to-mesenchymal transition through targeting ZEB2, MDM2, and TYMS [104]; miR-193-3p functions as a tumor-promoting microRNA by directly targeting PTEN in RCC [105]; miR-501-3p induces G1 phase arrest in RCC cells by targeting the Wilms’ tumor 1-associating protein (WTAP)–CDK2 axis [106]. This evidence concerns the gene CDK2 and renal cell carcinoma.